Eli Lilly (LLY) partners with Insilico Medicine in a $2.75B deal to develop AI-discovered drugs, with $115M upfront and milestone-based payments. The post Eli LillyEli Lilly (LLY) partners with Insilico Medicine in a $2.75B deal to develop AI-discovered drugs, with $115M upfront and milestone-based payments. The post Eli Lilly

Eli Lilly (LLY) Invests $2.75B in Insilico’s AI Drug Discovery Platform

2026/03/30 21:59
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Key Takeaways

  • Eli Lilly has partnered with Insilico Medicine in an agreement valued at up to $2.75 billion for AI-generated pharmaceutical development.
  • The Hong Kong biotech company will receive $115 million immediately, with additional payments contingent on achieving specific milestones and earning royalties.
  • This partnership builds on a 2023 collaboration focused on AI software licensing between the two organizations.
  • Insilico’s portfolio includes over 28 AI-designed drug candidates, with approximately 50% currently undergoing clinical evaluation.
  • The pharmaceutical giant obtains worldwide exclusive rights for development and commercialization of resulting therapies.

Eli Lilly is making a substantial commitment to artificial intelligence-driven pharmaceutical research through a landmark partnership with Insilico Medicine, headquartered in Hong Kong, valued at up to $2.75 billion.

Unveiled this past Sunday, the arrangement provides Insilico with an initial payment of $115 million. Additional compensation is contingent upon achieving regulatory approvals, commercial benchmarks, and generating royalty income from product sales.

The agreement grants Lilly worldwide exclusivity to advance and market any therapeutic compounds emerging from this collaboration. This represents significant strategic positioning for a pharmaceutical company already generating substantial revenue from its weight management medications.


LLY Stock Card
Eli Lilly and Company, LLY

Insilico has established itself as a leader in applying artificial intelligence throughout the complete drug discovery cycle — from target identification through molecular design. The organization reports creating over 28 pharmaceutical candidates using generative AI technology, with close to 50% currently advancing through clinical testing phases.

Following its Hong Kong stock market debut in December, Insilico’s shares have surged more than 50% so far this year.

This isn’t the companies’ first collaboration. Their initial partnership began in 2023 through an AI software licensing arrangement. The current agreement represents a dramatic expansion of that relationship.

Andrew Adams, who leads Molecule Discovery at Lilly as group vice president, characterized Insilico’s AI capabilities as “a powerful complement” to Lilly’s existing clinical research infrastructure. He emphasized that the alliance would enable exploration of novel therapeutic mechanisms and accelerate candidate identification across diverse therapeutic areas.

Artificial Intelligence Integration Throughout Drug Development

Insilico conducts its AI technology development primarily in Canada and Middle Eastern facilities, avoiding China for this work, though early-stage preclinical research occurs within Chinese borders. According to Zhavoronkov, AI-powered systems can generate molecular compounds significantly faster than conventional approaches, substantially reducing discovery timelines.

The agreement also brings Insilico into Lilly’s Gateway Labs ecosystem, a collaborative network for biotech innovation. The partnership hasn’t yet identified which specific therapeutic areas will be prioritized.

Lilly continues aggressive infrastructure expansion efforts. Current projects include a new research facility in San Francisco and significant investments in computational infrastructure. The company has also committed $3 billion to Chinese market development over the coming decade, despite China representing less than 3% of current revenues.

Strategic AI Investment Framework

CEO David Ricks participated in a prominent Beijing business forum this month, signaling the company’s increasing attention to China-based partnerships while simultaneously pursuing global expansion.

Lilly’s leadership has articulated a clear objective: leverage artificial intelligence to accelerate biological target discovery and diversify the pipeline beyond its current obesity treatment franchises.

This Insilico partnership provides Lilly with immediate access to one of the industry’s most sophisticated AI-powered drug discovery engines, complete with an established portfolio already progressing through clinical development stages.

The post Eli Lilly (LLY) Invests $2.75B in Insilico’s AI Drug Discovery Platform appeared first on Blockonomi.

Market Opportunity
Based Logo
Based Price(BASED)
$0.11983
$0.11983$0.11983
+199.57%
USD
Based (BASED) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

USDH Power Struggle Ignites Stablecoin “Bidding Wars” Across DeFi: Bloomberg

USDH Power Struggle Ignites Stablecoin “Bidding Wars” Across DeFi: Bloomberg

A heated contest for control over a new dollar-pegged token has set the stage for what analysts say could define the next phase of the stablecoin industry. According to Bloomberg, a bidding war unfolded on Hyperliquid, one of crypto’s fastest-growing trading platforms, with the prize being the right to issue USDH, its native stablecoin. The competition drew some of the sector’s most prominent names, including Paxos, Sky, and Ethena, who later withdrew their bid, alongside the lesser-known Native Markets, a startup backed by Stripe stablecoin subsidiary Bridge. Hyperliquid Stablecoin Race Shows Branding and Partnerships Matter as Much as Tech Over the weekend, Hyperliquid’s validators, the contributors who secure the network and vote on key decisions, awarded the USDH contract to Native Markets over the weekend. Despite its relatively new status, the firm’s connection with Stripe helped it outpace more established rivals. Stablecoins underpin decentralized finance by providing a dollar-backed medium for collateral, settlement, and payments across applications. What began as a grassroots, community-led sector has evolved into a battleground for institutions and payment companies seeking revenue from interest on reserves. Circle, for example, shares proceeds from its USDC with Coinbase under a partnership designed to stabilize earnings during market swings. The Hyperliquid contest offered a rare glimpse into just how intense competition has become. Paxos pledged to take no revenue until USDH surpassed $1 billion in circulation. Agora offered to share 100% of net revenue with Hyperliquid, while Ethena put forward 95%. All were outbid by Native Markets, whose ties to Stripe’s $1.1 billion acquisition of Bridge and subsequent rollout of the Tempo blockchain positioned it as a strong contender. “Every stablecoin issuer is extremely desperate for supply,” said Zaheer Ebtikar, co-founder of Split Capital. “They are willing to publicly announce how much they are willing to offer. It just shows it’s a very tough business for stablecoin issuers.” While USDC remains dominant on Hyperliquid with more than $5.6 billion in deposits, the arrival of USDH could shift flows and revenue dynamics. Paxos co-founder Bhau Kotecha said the firm sees the exchange’s growth as an important opportunity, while Agora’s co-founder Nick van Eck warned that awarding the contract to a vertically integrated issuer risked undermining decentralization. Regulatory positioning also factored into the debate. Paxos operates under a New York trust charter and is seeking a federal license, while Bridge holds money transmitter approvals in 30 states. Native Markets, in a blog post, cited regulatory flexibility and deployment speed as reasons for its selection. Hyperliquid said the strong engagement from its community validated the process. Circle CEO Jeremy Allaire dismissed concerns over USDC’s status, noting on X that competition benefits the ecosystem. Analysts suggested that fears of centralization may be exaggerated, noting that Hyperliquid is likely to remain neutral and support multiple stablecoins. Still, the contest over USDH highlighted a new reality for stablecoins: branding, partnerships, and business strategy are becoming as decisive as technology. Native Markets Secures USDH Stablecoin Mandate on Hyperliquid Hyperliquid has concluded its governance vote for the USDH stablecoin, awarding the mandate to Native Markets after a closely watched process that drew weeks of community debate and rival proposals. USDH, described by Hyperliquid as a “Hyperliquid-first, compliant, and natively minted” dollar-backed token, is intended to reduce the platform’s dependence on USDC and strengthen its spot markets. Validators on the decentralized exchange voted in favor of Native Markets, a relatively new player backed by Stripe’s Bridge subsidiary, over established contenders including Paxos and Ethena. The outcome followed a string of proposals offering aggressive revenue-sharing terms to win validator support, underscoring the scale of incentives attached to controlling USDH. Hyperliquid’s exchange has become a critical hub for stablecoin liquidity, with $5.7 billion in USDC, around 8% of its total supply, currently held on the network. At prevailing treasury yields, that translates to an estimated $200 million to $220 million in annual revenue for Circle, underlining why a native alternative could be transformative. Hyperliquid’s validators, who secure the network and vote on key decisions, selected Native Markets following an on-chain governance process that concluded September 15. Native Markets has laid out a phased rollout for USDH, beginning with capped minting and redemption trials before expanding into spot markets. Its reserves will be managed in cash and treasuries by BlackRock, with on-chain tokenization through Superstate and Bridge. Yield from those reserves will be split between Hyperliquid’s Assistance Fund and ecosystem development. The launch of USDH comes as Hyperliquid records record profits from perpetual futures trading, with $106 million in revenue in August alone, and prepares to slash spot trading fees by 80% to bolster liquidity. Analysts say the move positions Hyperliquid to capture more of the stablecoin economics internally, marking a significant step in its bid to rival the largest players in decentralized finance
Share
CryptoNews2025/09/18 00:48
Bitcoin Market Faces Renewed Pressure: What Lies Ahead?

Bitcoin Market Faces Renewed Pressure: What Lies Ahead?

The post Bitcoin Market Faces Renewed Pressure: What Lies Ahead? appeared on BitcoinEthereumNews.com. Recent data reveals heightened instability in the cryptocurrency
Share
BitcoinEthereumNews2026/03/31 01:21
BTC fell below $67,000, down 0.94% on the day.

BTC fell below $67,000, down 0.94% on the day.

PANews reported on March 31 that, according to OKX market data, BTC has just fallen below $67,000 and is currently trading at $66,989.20 per coin, down 0.94% on
Share
PANews2026/03/31 01:22